A leading force in cancer innovation is making real strides. Dr. Patrick Soon-Shiong & ImmunityBio are powering ahead with Anktiva, a groundbreaking IL-15 superagonist immunotherapy that activates & multiplies the body’s natural killer (NK) cells & memory T cells to precisely hunt down & destroy tumors.
Instead of harsh chemo that damages healthy cells & weakens immunity, Anktiva restores & strengthens the immune system for targeted, longer lasting attacks, offering hope for fewer side effects & better outcomes.
The visionary behind it,
@DrPatrick, surgeon, inventor & ImmunityBio’s Founder, Executive Chairman & Global Chief Scientific Officer.
Anktiva earned U.S. FDA approval in 2024 for BCG unresponsive non muscle invasive
#BladderCancer (NMIBC) with carcinoma in situ. In January 2026, the Saudi FDA granted accelerated approvals for:
• Anktiva checkpoint inhibitors in metastatic non small cell
#LungCancer (a world first for subcutaneous IL-15 therapy!)
•
#Anktiva BCG in BCG
unresponsive NMIBC
Plus, strong trial data show immune restoration, prolonged survival in tough cases & promising signals in lung, pancreatic, glioblastoma & more.
Sales are surging too. ImmunityBio reported ~$113 million in preliminary 2025 net product revenue, a massive 700% year over year jump!
Experts stay cautiously optimistic. More trials & approvals needed, but this “Immunotherapy 2.0” shift empowering the body’s natural defenses is changing the game toward smarter, kinder cancer care.
Hope is building as science advances. The future of fighting
#cancer looks brighter every day.